A Randomised, Double-blind, Placebo-Controlled, Dose-ranging, Parallel Design Study to Evaluate the Efficacy and Safety of the Endothelin Antagonist Avosentan in Patients With Diabetic Kidney Disease

Registry ID

EUCTR2008-000786-32

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Speedel Pharma Ltd

Start date

2008-06-17

Last update

2026-08-16

Conditions

• Diabetic kidney disease

Summary

To determine the dose-dependent effects of avosentan administered orally once daily on albuminuria, as measured by the albumin creatinine ratio (ACR), in type 2 diabetic patients with diabetic kidney disease

Locations

• , , Hungary
• , , Belgium
• , , Latvia
• , , Czechia
• , , Germany
• , , Slovakia

View on source registry